The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Open accessPublished version of a preprint
Abstract
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma, but the fraction of patients who derive clinical benefit remains undefined. Here, we report the experience of 860 patients with metastatic lung adenocarcinoma analyzed prospectively for mutations in >300 cancer-associated genes. Potentially actionable genetic events were stratified into one of four levels based upon published clinical or laboratory evidence that the mutation in question confers increased sensitivity to standard or investigational therapies. Overall, 37.1% (319/860) of patients received a matched therapy guided by their tumor molecular profile. Excluding alterations associated with standard-of-care therapy, 14.4% (69/478) received matched therapy, with a clinical benefit of 52%. Use of matched therapy was strongly influenced by the level of preexistent clinical evidence that the mutation identified predicts for drug response. Analysis of genes mutated significantly more often in tumors without known actionable mutations nominated STK11 and KEAP1 as possible targetable mitogenic drivers. Significance: An increasing number of therapies that target molecular alterations required for tumor maintenance and progression have demonstrated clinical activity in patients with lung adenocarcinoma. The data reported here suggest that broader, early testing for molecular alterations that have not yet been recognized as standard-of-care predictive biomarkers of drug response could accelerate the development of targeted agents for rare mutational events and could result in improved clinical outcomes. Cancer Discov; 7(6); 596–609. ©2017 AACR. See related commentary by Liu et al., p. 555. This article is highlighted in the In This Issue feature, p. 539
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [21]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Somatic mutations in LKB1 and KEAP1 significantly co-occur with mutant KRAS and with each other in NSCLC15, 59, 63, 91.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Although EGFR –mutant tumors represent the prototypical oncogene-addicted LUAD subgroup that spearheaded adoption of the single-driver model, the overwhelming majority of EGFR-mutant lung tumors harbor one or more co-mutations, even when the analysis is limited to pre-defined sets of cancer-relevant genes within established panels (FoundationOne, Guardant360, MSK-IMPACT)15, 59, 72, 73.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Self-citationIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Self-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citationUsing Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Self-citation
Research works printed but not linked: 2
- OncoKB.org, 2016, Precision Oncology Knowledge Base [Internet]
- Banno, 2016, : 10.1111/.12980, Sensitivities to various EGFR-TKIs of uncommon EGFR mutations L861Q and S768I: what is the optimal EGFR-TKI?, Cancer Sci · DOI
Cited by
Sorted by citations
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Self-citationTumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Self-citationOncoKB: A Precision Oncology Knowledge Base
Chakravarty, D., Gao, J., Phillips, S. M., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R. D., Soumerai, T. E., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,783
Self-citationThe 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Nicholson, A. G., Tsao, M., Beasley, M. B., Borczuk, A., Brambilla, E. M., Cooper, W. A., Đačić, S., Jain, D., Kerr, K. M., Lantuéjoul, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,656
Self-citationRizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367
Self-citationMolecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Rudin, C. M., Poirier, J. T., Byers, L. A., Dive, C., Dowlati, A., George, J., Heymach, J. V., Johnson, J. E. B., Lehman, J. M., MacPherson, D. P., et al. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0133-9 · Cited by 1,251
Self-citationTargeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer
Arbour, K. C., & Riely, G. J. (2019) · JAMA · doi:10.1001/jama.2019.11058 · Cited by 1,070
Self-citationCo-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Tan, A. C., & Tan, D. S. W. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01626 · Cited by 810
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780
Self-citationThe current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Benayed, R., Offin, M. D., Mullaney, K. A., Sukhadia, P., Rios, K., Desmeules, P., Ptashkin, R. N., Won, H. H., Chang, J. C., Halpenny, D. F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0225 · Cited by 495
Self-citationOffin, M. D., Chan, J. M., Tenet, M., Rizvi, H. A., Shen, R., Riely, G. J., Rekhtman, N., Daneshbod, Y., Quintanal-Villalonga, À., Penson, A. V., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.002 · Cited by 466
Self-citationLung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
Testa, U., Castelli, G., & Pelosi, E. (2018) · Cancers · doi:10.3390/cancers10080248 · Cited by 417
Megyesfalvi, Z., Gay, C. M., Popper, H., Pirker, R., Ostoros, G., Heeke, S., Lang, C., Höetzenecker, K., Solta, A., Boettiger, K., et al. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21785 · Cited by 390
Cho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., Choi, Y. H., Ahn, M. S., Lee, M. H., Sun, J.-M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00931 · Cited by 358
EGFR signaling pathway as therapeutic target in human cancers
Levantini, E., Maroni, G., Re, M. D., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 390
Offin, M. D., Rizvi, H. A., Tenet, M., Ni, A., Sánchez-Vega, F., Li, B. T., Drilon, A. E. D. C., Kris, M. G., Rudin, C. M., Schultz, N. D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1102 · Cited by 336
Self-citationRekhtman, N., Montecalvo, J., Chang, J. C., Alex, D., Ptashkin, R. N., Ai, N., Sauter, J. L., Kezlarian, B. E., Jungbluth, A. A., Desmeules, P., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.023 · Cited by 325
Self-citationKRAS-Mutant non-small cell lung cancer: From biology to therapy
Ferrer, I., Zugazagoitia, J., Herbertz, S., John, W. J., Paz-Ares, L. G., & Schmid‐Bindert, G. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.013 · Cited by 315
ROS1-dependent cancers — biology, diagnostics and therapeutics
Drilon, A. E. D. C., Jenkins, C., Iyer, S. R., Schoenfeld, A. J., Keddy, C., & Davare, M. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0408-9 · Cited by 304
Self-citationNegrao, M. V., Skoulidis, F., Montesion, M., Schulze, K., Bāra, I., Shen, V., Xu, H., Hu, S., Sui, D., Elamin, Y. Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002891 · Cited by 307
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
Li, B. T., Michelini, F., Misale, S., Cocco, E., Baldino, L., Cai, Y., Shifman, S. G., Tu, H., Myers, M. L., Xu, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0215 · Cited by 293
Self-citationLiu, C., Zheng, S., Jin, R., Wang, X., Wang, F., Zang, R., Xu, H., Lu, Z., Huang, J., Lei, Y., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.027 · Cited by 288
Exploring Targeted Degradation Strategy for Oncogenic KRASG12C
Zeng, M., Xiong, Y., Safaee, N., Nowak, R. P., Donovan, K. A., Yuan, C. J., Nabet, B., Gero, T. W., Feru, F., Li, L., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.12.006 · Cited by 275
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
Majeed, U., Manochakian, R., Zhao, Y., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01121-2 · Cited by 283
Koga, T., Suda, K., Fujino, T., Ohara, S., Hamada, A., Nishino, M., Chiba, M., Shimoji, M., Takemoto, T., Arita, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.015 · Cited by 265
Melosky, B. L., Kambartel, K.-O., Häntschel, M., Bennetts, M., Nickens, D. J., Brinkmann, J., Kayser, A., Moran, M., & Cappuzzo, F. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00563-1 · Cited by 287
Yu, H. A., Suzawa, K., Jordan, E., Zehir, A., Ni, A., Kim, R., Kris, M. G., Hellmann, M. D., Li, B. T., Somwar, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2961 · Cited by 259
Self-citationSelecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00520-1 · Cited by 257
Wohlhieter, C. A., Richards, A. L., Uddin, F. Z., Hulton, C. H., Quintanal-Villalonga, À., Martin, A. S., de Stanchina, E., Bhanot, U. K., Asher, M., Shah, N., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108444 · Cited by 253
Self-citationClinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 241
Self-citationTargeting MET Dysregulation in Cancer
Recondo, G., Che, J., Janne, P. A., & Awad, M. M. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1446 · Cited by 235
Precision medicine in non-small cell lung cancer: Current applications and future directions
Yang, S., Schultheis, A. M., Yu, H. A., Mandelker, D. L., Ladanyi, M., & Büttner, R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.009 · Cited by 220
Self-citationAisner, D. L., Sholl, L. M., Berry, L. D., Rossi, M. R., Chen, H., Fujimoto, J., Moreira, A. L., Ramalingam, S. S., Villaruz, L. C., Otterson, G. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2289 · Cited by 206
Self-citationPrecision Management of Advanced Non–Small Cell Lung Cancer
Yang, C., Yang, J. C., & Yang, P. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051718-013524 · Cited by 212
Zhang, C., Zhang, J. J., Xu, F.-P., Wang, Y.-G., Xie, Z., Su, J., Dong, S., Nie, Q., Shao, Y. W., Zhou, Q. H., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.031 · Cited by 203
Santoni‐Rugiu, E., Melchior, L. C., Urbanska, E. M., Jakobsen, J. N., de Stricker, K., Grauslund, M., & Sørensen, J. B. (2019) · Cancers · doi:10.3390/cancers11070923 · Cited by 202
Fujino, T., Kobayashi, Y., Suda, K., Koga, T., Nishino, M., Ohara, S., Chiba, M., Shimoji, M., Tomizawa, K., Takemoto, T., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.023 · Cited by 186
Liu, C., Zheng, S., Wang, Z., Wang, S., Wang, X., Yang, L., Xu, H., Cao, Z., Feng, X., Xue, Q., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12327 · Cited by 187
Mack, P. C., Banks, K. C., Espenschied, C. R., Burich, R. A., Zill, O. A., Lee, C. E., Riess, J. W., Mortimer, S., Talasaz, A. H., Lanman, R. B., et al. (2020) · Cancer · doi:10.1002/cncr.32876 · Cited by 172
Fagan, R. J., & Dingwall, A. K. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.024 · Cited by 177
Remón, J., Passiglia, F., Ahn, M., Barlési, F., Forde, P. M., Garon, E. B., Gettinger, S. N., Goldberg, S. B., Herbst, R. S., Horn, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.006 · Cited by 171
Jiang, N., Zou, C., Zhu, Y., Luo, Y., Chen, L., Lei, Y., Tang, K., Sun, Y., Zhang, W., Li, S., et al. (2020) · Theranostics · doi:10.7150/thno.41120 · Cited by 153
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Liang, Y., Wang, H., Chen, B., Mao, Q., Xia, W., Zhang, T., Song, X., Zhang, Z., Xu, L., Dong, G., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.11.012 · Cited by 149
Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening
Li, Z., Qian, Y., Li, W., Liu, L., Yu, L., Liu, X., Wu, G., Wang, Y., Luo, W., Fang, F., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101411 · Cited by 136
Dagogo-Jack, I., Martinez, P., Yeap, B. Y., Ambrogio, C., Ferris, L. A., Lydon, C., Nguyen, T., Jessop, N. A., Iafrate, A. J., Johnson, B. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2062 · Cited by 130
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
Moya‐Horno, I., Viteri, S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017745012 · Cited by 134
Chang, J. C., Montecalvo, J., Borsu, L. A., Lu, S., Larsen, B. T., Wallace, W. D., Sae‐Ow, W., Mackinnon, A. C., Kim, H. R., Bowman, A. S., et al. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001086 · Cited by 131
Self-citationArbour, K. C., Rizvi, H. A., Plodkowski, A. J., Hellmann, M. D., Knežević, A., Heller, G., Yu, H. A., Ladanyi, M., Kris, M. G., Arcila, M. E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4023 · Cited by 130
Self-citationMolecular Pathology of Primary Non-small Cell Lung Cancer
Suster, D. I., & Mino-Kenudson, M. A. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.08.004 · Cited by 130
Genome-wide identification and analysis of prognostic features in human cancers
Smith, J. C., & Sheltzer, J. M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110569 · Cited by 123
Suzawa, K., Offin, M. D., Lu, D., Kurzatkowski, C., Vojnic, M., Smith, R. S., Sabari, J. K., Tai, H., Mattar, M. S., Khodos, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1640 · Cited by 129
Self-citationA Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers
Sabari, J. K., Offin, M. D., Stephens, D. P., Ni, A., Lee, A. V., Pavlakis, N., Clarke, S. J., Diakos, C. I., Datta, S., Tandon, N., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy156 · Cited by 123
Self-citationRare molecular subtypes of lung cancer
Harada, G., Yang, S., Cocco, E., & Drilon, A. E. D. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00733-6 · Cited by 126
Self-citationKRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
Lim, T. K. H., Skoulidis, F., Kerr, K. M., Ahn, M., Kapp, J. R., Soares, F. A., & Yatabe, Y. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107293 · Cited by 133
Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing
Cohen, D. B., Hondelink, L. M., Solleveld‐Westerink, N., Kolkman-Uljee, S. M., Ruano, D., Cleton-Jansen, A., von der Thüsen, J. H., Ramai, S. R. S., Postmus, P. E., van Roggen, J. F. G., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.019 · Cited by 123
König, D., Prince, S. S., & Rothschild, S. I. (2021) · Cancers · doi:10.3390/cancers13040804 · Cited by 119
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo
Foggetti, G., Li, C., Cai, H., Hellyer, J. A., Lin, W.-Y., Ayeni, D. O., Hastings, K., Choi, J., Wurtz, A., Andrejka, L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1385 · Cited by 113
Best, S. A., Ding, S., Kersbergen, A., Dong, X., Song, J.-Y., Xie, Y., Reljic, B., Li, K., Vince, J. E., Rathi, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12164-y · Cited by 108
A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma
Jones, G. D., Brandt, W. S., Shen, R., Sánchez-Vega, F., Tan, K. S., Martin, A. S., Zhou, J. H., Berger, M. F., Solit, D. B., Schultz, N. D., et al. (2020) · JAMA Surgery · doi:10.1001/jamasurg.2020.5601 · Cited by 116
Self-citationChoudhury, N. J., Marra, A., Sui, J. S. Y., Flynn, J. R., Yang, S., Falcon, C. J., Selenica, P., Schoenfeld, A. J., Rekhtman, N., Gomez, D. R., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.11.022 · Cited by 123
Self-citationChang, J. C., Alex, D., Bott, M. J., Tan, K. S., Seshan, V., Golden, A., Sauter, J. L., Buonocore, D. J., Vanderbilt, C., Gupta, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1700 · Cited by 111
Self-citationSitthideatphaiboon, P., Galán‐Cobo, A., Negrao, M. V., Qu, X. H., Poteete, A., Zhang, F., Liu, D. D., Lewis, W. E., Kemp, H. N., Lewis, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2859 · Cited by 115
Chang, J. C., Offin, M. D., Falcon, C. J., Brown, D. N., Houck-Loomis, B. R., Meng, F., Rudneva, V. A., Won, H. H., Amir, S., Montecalvo, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0423 · Cited by 107
Self-citationRotow, J. K., Gui, P., Wu, W., Raymond, V. M., Lanman, R. B., Kaye, F. J., Peled, N., de la Cruz, F. F., Nadres, B., Corcoran, R. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1667 · Cited by 109
PLK1 inhibition-based combination therapies for cancer management
Su, S., Chhabra, G., Singh, C. K., Ndiaye, M. A., & Ahmad, N. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101332 · Cited by 105
KRAS G12C–Mutant Non–Small Cell Lung Cancer
Veluswamy, R., Mack, P. C., Houldsworth, J., Elkhouly, E., & Hirsch, F. R. (2021) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.02.002 · Cited by 96
Volckmar, A., Leichsenring, J., Kirchner, M., Christopoulos, P., Neumann, O., Budczies, J., de Oliveira, C. M. M., Rempel, E., Buchhalter, I., Brandt, R., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32133 · Cited by 102
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
Subramanian, J., Katta, A., Masood, A., Vudem, D. R., & Kancha, R. K. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0845 · Cited by 105
Overexpression of GSDMC is a prognostic factor for predicting a poor outcome in lung adenocarcinoma
Wei, J., Xu, Z., Chen, X., Wang, X., Zeng, S., Qian, L., Yang, X., Ou, C., Lin, W., Gong, Z., et al. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10837 · Cited by 100
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
Mizuta, H., Okada, K., Araki, M., Adachi, J., Takemoto, A., Kutkowska, J., Maruyama, K., Yanagitani, N., Oh‐hara, T., Watanabe, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21396-w · Cited by 97
Schüler, M., Berardi, R., Lim, W., de Jonge, M. J. A., Bauer, T. M., Azaro, A., Gottfried, M., Han, J., Lee, D. H., Wollner, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.293 · Cited by 97
Machine learning application in personalised lung cancer recurrence and survivability prediction
Yang, Y., Xu, L., Sun, L., Zhang, P., & Farid, S. S. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.03.035 · Cited by 103
Conway, A., Mitchell, C. L., Kilgour, E., Brady, G., Dive, C., & Cook, N. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0332-2 · Cited by 95
Offin, M. D., Somwar, R., Rekhtman, N., Benayed, R., Chang, J. C., Plodkowski, A. J., Lui, A. J. W., Eng, J., Rosenblum, M. K., Li, B. T., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00126 · Cited by 99
Self-citationPlagnol, V., Woodhouse, S., Howarth, K., Lensing, S. V., Smith, M. J., Epstein, M., Madi, M., Smalley, S., Leroy, C., Hinton, J., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193802 · Cited by 94
Identification of a highly lethal V3 + TP53 + subset in ALK + lung adenocarcinoma
Christopoulos, P., Kirchner, M., Bozorgmehr, F., Endris, V., Elsayed, M., Budczies, J., Ristau, J., Penzel, R., Herth, F. J. F., Heußel, C. P., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31893 · Cited by 93
Timing and Origins of Local and Distant Metastases in Lung Cancer
Tang, W., Wu, M., Bao, H., Xu, Y., Lin, J., Liang, Y., Zhang, Y., Chu, X., Qiu, Z., Su, J., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.02.023 · Cited by 89
Hayashi, T., Desmeules, P., Smith, R. S., Drilon, A., Somwar, R., & Ladanyi, M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2343 · Cited by 90
Self-citationFrequency and outcomes of brain metastases in patients with HER2‐mutant lung cancers
Offin, M. D., Feldman, D., Ni, A., Myers, M. L., Lai, W. V., Pentsova, E. I., Boire, A. A., Daras, M., Jordan, E., Solit, D. B., et al. (2019) · Cancer · doi:10.1002/cncr.32461 · Cited by 89
Self-citationHazafa, A., Mumtaz, M., Farooq, M. F., Bilal, S., Chaudhry, S. N., Firdous, M., Naeem, H., Ullah, M. O., Yameen, M., Mukhtiar, M., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118525 · Cited by 98
Widyananda, M. H., Pratama, S. K., Samoedra, R. S., Sari, F. N., Kharisma, V. D., Ansori, A. N. M., & Antonius, Y. (2021) · Journal of Pharmacy & Pharmacognosy Research · doi:10.56499/jppres21.1047_9.4.484 · Cited by 88
RHO GTPases in cancer: known facts, open questions, and therapeutic challenges
Bustelo, X. R. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170531 · Cited by 89
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 98
Bracht, J. W. P., Mayo‐de‐las‐Casas, C., Berenguer, J., Karachaliou, N., & Rosell, R. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0720-z · Cited by 86
MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING
Zhang, Y., Yang, Q., Zeng, X., Wang, M., Dong, S., Yang, B., Tu, X., Wei, T., Xie, W., Zhang, C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1500 · Cited by 82
Zugazagoitia, J., Ramos, I. C., Trigo, J. M., Palka, M., Gómez‐Rueda, A., Lewintre, E. J., Camps, C., Isla, D., Iranzo, P., Ponce-Aix, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy512 · Cited by 85
Fujino, T., Suda, K., & Mitsudomi, T. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s269307 · Cited by 85
Landre, T., Justeau, G., Assié, J., Chouahnia, K., Davoine, C., Taleb, C., CHOUAID, C., & Duchemann, B. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03031-1 · Cited by 84
Lee, J. W., Zhang, Y. X., Eoh, K. J., Sharma, R., Sanmamed, M. F., Wu, J. Q., Choi, J., Park, H. S., Iwasaki, A., Kaftan, E. J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.004 · Cited by 81
Stoy, S., Segal, J. P., Mueller, J. S., Furtado, L. V., Vokes, E. E., Patel, J. D., & Murgu, S. D. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.11.010 · Cited by 80
Shiba‐Ishii, A., Johnson, T. W., Dagogo‐Jack, I., Mino-Kenudson, M. A., Johnson, T. R., Wei, P. Y., Weinrich, S. L., McTigue, M. A., Walcott, M., Nguyen-Phuong, L., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00399-6 · Cited by 80
Rix, L. L. R., Sumi, N. J., Hu, Q., Desai, B., Bryant, A. T., Li, X., Welsh, E. A., Fang, B., Kinose, F., Kuenzi, B. M., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abj5879 · Cited by 76
Guercio, B. J., Sarfaty, M., Teo, M. Y., Ratna, N., Düzgöl, C., Funt, S. A., Lee, C., Aggen, D. H., Regazzi, A. M., Chen, Z., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1283 · Cited by 81
Self-citationArrieta, O. G., Avilés‐Salas, A., Orozco‐Morales, M., Hernández‐Pedro, N., Cardona, A. F., Cabrera-Miranda, L. A., Barrios‐Bernal, P., Soca‐Chafre, G., Cruz‐Rico, G., Peña-Torres, M. D. L., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2882 · Cited by 76
Zhou, Z., Ding, Z., Yuan, J., Shen, S., Jian, H., Tan, Q., Yang, Y., Chen, Z., Luo, Q., Cheng, X., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01283-7 · Cited by 79
Metadata
- Authors
- Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., Jayakumaran, G., Gao, S. P., Johnsen, H. C., Hanrahan, A. J., Zehir, A., Rekhtman, N., Ginsberg, M. S., Li, B. T., Yu, H. A., Paik, P. K., Drilon, A., Hellmann, M. D., Reales, D. N., Benayed, R., Rusch, V. W., Kris, M. G., Chaft, J. E., Baselga, J., Taylor, B. S., Schultz, N., Rudin, C. M., Hyman, D. M., Berger, M. F., Solit, D. B., Ladanyi, M., & Riely, G. J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- 6Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Corresponding author
- Riely, Gregory J.
- ORCID
- Jordan, Emmet J.
- Kim, Hyunjae R.
- Arcila, Maria E.
- Chakravarty, Debyani
- Gao, JianJiong
- Kundra, Ritika
- Jonsson, Philip
- Jayakumaran, Gowtham
- Zehir, Ahmet
- Rekhtman, Natasha
- Ginsberg, Michelle S.
- Li, Bob T.
- Yu, Helena A.
- Paik, Paul K.
- Drilon, Alexander
- Hellmann, Matthew D.
- Reales, Dalicia N.
- Benayed, Ryma
- Rusch, Valerie W.
- Kris, Mark G.
- Chaft, Jamie E.
- Taylor, Barry S.
- Schultz, Nikolaus
- Rudin, Charles M.
- Hyman, David M.
- Berger, Michael F.
- Solit, David B.
- Ladanyi, Marc
- Riely, Gregory J.
- Venue
- Cancer Discovery
- Published
- 2017-06-01
- Volume
- 7
- Issue
- 6
- Pages
- 596-609
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5482929
- OpenAlex
- W2603411876
- Cited by
- 643
- References
- 49
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 65 · 2023: 99 · 2022: 94 · 2021: 101 · 2020: 79 · 2019: 65 · 2018: 55 · 2017: 12
- FWCI
- 47.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR002384)
- National Cancer Institute (P30CA008748)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- lung adenocarcinoma, metastatic lung cancer, actionable mutations, targeted therapy, predictive biomarkers, drug response, STK11, Keap1, clinical benefit, molecular profiling
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Adolescent, Adult, Aged, Female, Genetic Testing, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Biomarkers, Tumor, Young Adult, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
